Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial
- 25 December 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of Sport Medicine
- Vol. 28 (1), e1-e13
- https://doi.org/10.1097/mjt.0000000000001303
Abstract
Background: This study evaluated the potential of activating the fuel-sensing enzymes Adenine monophosphate (AMP)-activated protein kinase and the deacetylase sirtuin1, to promote weight loss. We tested the efficacy of a fixed dose combination of the amino acid leucine and 2 well-characterized agents with established safety profiles to modulate energy metabolism and facilitate weight loss. Study Question: Will a combination of l-leucine with low-dose metformin and sildenafil produce a novel synergistic interaction that reduces body weight? Study Design: We conducted a 24-week randomized controlled trial evaluating the effect on weight loss of leucine 1.1 g and sildenafil 1.0 mg or 4.0 mg, with and without metformin 500 mg (Leu/Sil 1.0, Leu/Sil 4.0, Leu/Met/Sil 1.0, and Leu/Met/Sil 4.0 twice/day). We enrolled 267 participants who were 18–65 years of age without diabetes and with the body mass index (BMI) of 30–45 kg/m2. Measures and Outcomes: The primary endpoint was percentage weight change after 24 weeks. Adverse events were evaluated. The primary analysis was performed using the perprotocol population analysis of covariance estimation. Subgroup analyses of patients residing above certain threshold limits at baseline and in populations at increased risk of obesity were assessed post-hoc as exploratory end points. Results: Placebo-adjusted mean bodyweight reductions in the Leu/Met/Sil 1.0, Leu/Met/Sil 4.0, and Leu/Sil 4.0 groups were −1.99%, −1.69%, and −1.67% (P = 0.015, 0.035, and 0.036, respectively). The most common adverse events were gastrointestinal-related and occurred in the metformin-treated groups consistent with metformin treatment. In African Americans, Leu/Met/Sil 1.0 produced 5.4% mean weight loss. In participants with BMI 2 treated with Leu/Met/Sil 1.0, the weight loss increased to 2.84%, particularly in participants with baseline insulin ≥12mU/L (3.5%). Conclusions: Leu/Met/Sil 1.0 and 4.0 and Leu/Sil 4.0 reduced body weight, but Leu/Met/Sil 1.0 was associated with robust weight loss in African Americans, and individuals with BMI 30–39.9 kg/m2, especially participants with hyperinsulinemia.Keywords
This publication has 25 references indexed in Scilit:
- The mechanisms of action of metforminDiabetologia, 2017
- The Hunger Genes: Pathways to ObesityCell, 2015
- The role for adipose tissue in weight regain after weight lossObesity Reviews, 2015
- Synergistic Effects of Polyphenols and Methylxanthines with Leucine on AMPK/Sirtuin-Mediated Metabolism in Muscle Cells and AdipocytesPLOS ONE, 2014
- A Two-Year Randomized Trial of Obesity Treatment in Primary Care PracticeThe New England Journal of Medicine, 2011
- Effects of dairy consumption on SIRT1 and mitochondrial biogenesis in adipocytes and muscle cellsNutrition & Metabolism, 2011
- AMPK and SIRT1: a long-standing partnership?American Journal of Physiology-Endocrinology and Metabolism, 2010
- SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein KinaseOnline Journal of Public Health Informatics, 2008
- Metabolic and weight-loss effects of a long-term dietary intervention in obese patientsThe American Journal of Clinical Nutrition, 1999
- Discrepancy between Self-Reported and Actual Caloric Intake and Exercise in Obese SubjectsThe New England Journal of Medicine, 1992